Ticker Hub
HROW — AI Analysis & Sentiment
4 recent AI-generated analyses for HROW. Sentiment and confidence insights updated continuously.
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
CMS's J-Code for IOPIDINE® 1% significantly improves its commercial viability by enabling direct reimbursement, which should boost adoption and sal...
Apr 16, 2026Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Harrow's new $50 million debt offering significantly increases its financial risk, especially given its already high leverage and unprofitability, ...
Mar 24, 2026Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
Harrow announced the initiation of a Phase 3 clinical trial for TRIESENCE, which could expand its label to treat ocular inflammation after cataract...
Mar 3, 2026Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
Harrow Health announced its Q4 2025 financial results and provided guidance for 2026. This is important as it could indicate growth potential and a...
Mar 2, 2026